Zhaohui Peng

home / authors / zhaohui-peng

Dr. Zhaohui Peng is the chairman, chief executive officer, and founder of Shenzhen SiBiono GeneTech Co., Ltd., Langshen Road, Shenzhen Hi-Tech Industrial Park, Shenzhen, China, 0755.2696.8818, fax: 0755.2696.8808, sbn@sibiono.com; www.sibiono.com.

Articles

Points to Consider for Human Gene Therapy and Product Quality Control State Food and Drug Administration of China

State Food and Drug Administration of China;Zhaohui Peng

May 1st 2004

Introduction - Gene therapy is a medical intervention based on the modification of the genetic material of living cells. Currently, gene therapy is restricted in application to somatic cells.

The Genesis of Gendicine: The Story Behind the First Gene Therapy

Zhaohui Peng

May 1st 2004

In October 2003, Shenzhen SiBiono GeneTech made history by becoming the first company approved to market a gene therapy medication. China's State Food and Drug Administration (SFDA) approved Gendicine for treatment of head and neck squamous cell carcinoma (HNSCC). SiBiono believes that continued clinical trials will prove Gendicine to be effective as a wide-spectrum anticancer agent.